GlassScriptPhysician profile
Luna U Sy
NPI 1356455497
$2,710.29
in general payments reported to CMS, 2019-2025
18 companies · $66.61 in 2025
The $66.61 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $433 · 2021: $510 · 2022: $493 · 2023: $448 · 2024: $375 · 2025: $66.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $36.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.32 |
| Education | $36.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $601.50 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $404.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $370.52 | 2022-2025 | |
| Amgen INC. | $285.60 | 2020-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $260.59 | 2019-2023 | Verquvo, Belsomra |
| Novo Nordisk INC | $185.50 | 2020-2022 | |
| Glaxosmithkline, LLC. | $156.93 | 2020-2024 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $112.86 | 2020-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $85.70 | 2019 | |
| Eisai INC. | $63.27 | 2020-2021 | |
| Amarin Pharma, INC. | $46.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.90 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $18.87 | 2019 | |
| Abbott Laboratories | $17.97 | 2022 | |
| Axsome Therapeutics, INC. | $16.18 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.27 | 2019 | |
| Impel Pharmaceuticals INC. | $14.13 | 2023 | Trudhesa |
| Sanofi-Aventis U.S. LLC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luna Sy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.